N-phenylacetyl-L-propylglycine ethyl ester
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) 10 mg Auxiliary substances: potato starch - 13.5 mg, lactose monohydrate - 55 mg, microcrystalline cellulose - 21.2 mg, magnesium stearate - 0.3 mg, povidone (polyvinylpyrrolidone, povidone K-25) - 0.0008 mg.
Noopept has nootropic and neuroprotective properties. Improves learning ability and memory, acting on all phases of processing: initial information processing, consolidation, extraction. Interferes with the development of amnesia caused by electroshock, blockade of central cholinergic structures, glutamatergic receptor systems, deprivation of the paradoxical sleep phase. The neuroprotective (protective) effect of the drug Noopept manifests itself in increasing the resistance of brain tissue to damaging effects (trauma, hypoxia, electroconvulsive, toxic) and reducing the degree of damage to brain neurons. The drug reduces the focus on the thrombotic stroke model and prevents neuronal death in the tissue culture of the cerebral cortex and cerebellum exposed to neurotoxic concentrations of glutamate, free-radical oxygen. Noopept has an antioxidant effect, blocks the potential-dependent calcium channels of neurons, weakens the neurotoxic effect of excess calcium, improves the rheological properties of blood, and has antiaggregant, fibrinolytic, anticoagulant properties. The nootropic effect of the drug is associated with the formation of cycloprolylglycine, which is similar in structure to an endogenous cyclic dipeptide with antiamnesic activity, as well as with the presence of a cholinopositive effect. Noopept increases the amplitude of the transcallosal response, facilitating the associative connections between the hemispheres of the brain at the level of cortical structures. Contributes to the restoration of memory and other cognitive functions impaired as a result of damaging effects - brain injury, local and global ischemia, prenatal damage (alcohol, hypoxia). The therapeutic effect of the drug in patients with organic disorders of the central nervous system occurs from 5-7 days of treatment.Initially, the anxiolytic and light stimulating effects that are present in the activity spectrum of the Noopept drug are realized, manifested in the reduction or disappearance of anxiety, increased irritability, affective lability, and sleep disorders. After 14-20 days of therapy, a positive effect of the drug on cognitive functions, parameters of attention and memory is revealed. Noopept has a vegetative-normalizing effect, helps to reduce headaches, orthostatic disorders, tachycardia. When discontinuing the drug is not observed withdrawal syndrome. It has no damaging effect on the internal organs; does not lead to changes in the cellular composition of blood and biochemical parameters of blood and urine; does not possess immunotoxic, teratogenic effect, does not show mutagenic properties.
Absorption and distribution N-phenylacetyl-L-prolylglycine ethyl ester, being absorbed from the gastrointestinal tract, flows unchanged to the systemic circulation. It penetrates the BBB, is determined in the brain in greater concentrations than in the blood. The average time to reach Cmax is 15 minutes. Metabolism and removal of T1 / 2 from blood plasma - 0.38 hours. Partially stored unchanged, partially metabolized to form phenylacetic acid, phenylacetylproline and cycloprolylglycine. It has a high relative bioavailability (99.7%), does not accumulate in the body, does not cause drug dependence.
Impaired memory, attention, other cognitive functions and emotional labile disorders (including in elderly patients) with: - the effects of a head injury; - postcommutation syndrome; - cerebral vascular insufficiency (encephalopathies of various origins); - asthenic disorders; - other conditions with signs of reduced intellectual productivity.
- severe liver dysfunction; - pronounced renal dysfunction; - pregnancy; - lactation period; - age up to 18 years; - Lactase deficiency, lactose intolerance, glucose-galactose malabsorption; - hypersensitivity to the drug.
Use during pregnancy and lactation
The drug is contraindicated for use in pregnancy.If necessary, the use of the drug during lactation should decide on the termination of breastfeeding.
Dosage and administration
The drug is used inside, after meals. The initial dose of 20 mg / day is divided into 2 doses: 10 mg in the course of the day (morning and afternoon). With insufficient efficacy of therapy and with good tolerability of the drug, the dose is increased to 30 mg, distributing it to 3 doses of 10 mg during the day. Do not take the drug later than 18 hours. The duration of the course of treatment is 1.5-3 months. Repeated treatment if necessary can be carried out after 1 month.
Possible: allergic reactions. In patients with arterial hypertension, mostly severe, an increase in blood pressure may be observed while taking the drug.
Specific manifestations of overdose is not installed.
Interaction with other drugs
The interaction of the drug Noopept with alcohol, hypnotic drugs and antihypertensive drugs and psychogogic drugs has not been established.
If you need to increase the dose of the drug (up to 30 mg / day), with prolonged use, as well as with simultaneous use with other drugs, the occurrence of adverse reactions or worsening of the patient's condition should consult a doctor. Influence on the ability to drive motor vehicles and control mechanisms Noopept does not affect the ability to drive mechanisms and vehicles.